Alvotech is trading 10.8% up at ISK 431 on a technical rebound following several sessions of weakness and elevated investor concerns regarding earnings and biosimilar-sector risks.
- The move appears to be a short-term sentiment shift rather than a fundamental catalyst, as no fresh company-specific news or rating changes have been reported.
- The stock's performance stands in contrast to the broader biotech sector, which is trading lower today.